Vivek Ramaswamy Quotes

The old ethic for medicine [regarding new drugs] used to be: Is it safe and what are the risks? That is no longer adequate. Now people ask, "What goal are we reaching for?

It seems paradoxical that, as medical scientists make huge advances in discovering the mechanisms of common diseases, fewer and fewer innovative drugs are reaching the market.

Practically every day, there is a story in the newspapers about a new breakthrough drug on Parkinson's.

There's always going to be the need for new medications, better medications.

It took 23 years from Abraxane being conceived to us showing now with conclusiveness that it works in pancreatic cancer. We cannot afford as a society to wait another 23 years to make sure that the patients get the right care, at the right time, at the right place.

In general, drug companies are reasonably good at developing new treatments, and there's also a lot of good in the industry.

Perhaps the most useful lesson which has come out of the work on penicillin has been the demonstration that success in this field depends on the development and coordinated use of technical methods.

Huge sums are invested globally in medical research and development - and with good reason.

New drugs and surgical techniques offer promise in the fight against cancer, Alzheimer's, tuberculosis, AIDS, and a host of other life-threatening diseases. Animal research has been, and continues to be, fundamental to advancements in medicine.

I have an obligation to use what I know to try to bring real, usable medical science to every doctor and bedside and patient.

The United States has an active pharmaceutical industry that has brought huge benefits to the U.S. public. Most Americans, who benefit from these advances, have little understanding of how difficult it is to create an important new medical therapy and make it available to improve public health.

There is probably a promising drug candidate that has already been discovered for the treatment of Down syndrome that is sitting on the shelf of some drug company.

The discovery of artemisinin was an example of successful collective efforts.

I can't comment on the internal decision-making at other companies, but RVT-101 has the potential to be a very valuable product in the treatment of Alzheimer's, which is a huge unmet medical need.

To start with, pharma was an industry based on innovation, drug discovery.

I agree, the world would be a better place if doctors were less enthusiastic about adopting very new drugs.

Over the years, HIV/AIDS activists and their allies have been pioneers in creating new frontiers in the medical establishment. Through their efforts, the FDA drug approval procedures were reformed so promising new therapies could reach desperate patients quicker.

No matter how counter-intuitive it may seem, basic research has proven over and over to be the lifeline of practical advances in medicine.

I do not believe that Congress or the Administration should prohibit the medical community from pursuing a promising avenue of research that may improve the lives of millions of Americans.

Now, what tends to happen is that the stories get hyped. And the medicines are not quite as revolutionary and as dramatic as they seem to be. But, certainly, various phases of this problem are being attacked by the pharmaceutical companies.

I think that in the 21st century, medical biology will advance at a more rapid pace than before.

I keep encouraging the pharmaceutical companies to put more money into R&D.

I'd like to focus on my life on creating new medicines for people who are suffering from rare disease.

If you put me in charge of the medical research budget, I would cancel all primary research, I would cancel all new trials, for just one year, and I would spend the money exclusively on making sure that we make the best possible use of the clinical evidence that we already have.

Paradoxically, no such embargo exists for the drugs and therapies that have revolutionized the treatment of serious diseases although many of them were created with the same technologies.